Advertisement

Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor

  • Susanne Isfort
  • Martina Crysandt
  • Deniz Gezer
  • Steffen Koschmieder
  • Tim H. Brümmendorf
  • Dominik Wolf
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 212)

Abstract

Bosutinib is one of the five tyrosine kinase inhibitors which are currently approved for the treatment of chronic myeloid leukemia. By its dual inhibition of Src and ABL kinase and also targeting further kinases, it creates a unique target portfolio which also explains its unique side effect profile. The approval of bosutinib in 2013 made the drug available for patients previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options. As initially the first-line clinical trial comparing bosutinib with imatinib in CML patients in chronic phase did not reach its primary endpoint and therefore the product was not licensed for first-line therapy, a second first-line trial, the so-called BFORE study, was performed and just recently the promising results have been published predicting a quick expansion of the existing label. In comparison with the other approved TKIs, bosutinib harbors a distinct side effect profile with only very few cardiovascular and thromboembolic events and minimal long-term safety issues with most adverse events happening during the first months of treatment. On the other hand, gastrointestinal side effects are very common (e.g., diarrhea rates in more than 80% of the patients) with bosutinib surprising some of the investigators during the early clinical trials evaluating bosutinib. Until then, several approaches have been used to face this problem resulting in extensive supportive efforts (such as early loperamid treatment) as well as new trials testing alternative dosing strategies with early dose adjustment schedules. This article reports preclinical and clinical data available for bosutinib both in hematologic diseases such as CML or ALL and solid tumours as well as other diseases and envisions future perspectives including additional patient groups in which bosutinib might be of clinical benefit.

Keywords CML Tyrosine kinase inhibitor Bosutinib 

References

  1. Abbas R, Leister C, Sonnichsen D (2013) A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig 33(8):589–595CrossRefPubMedGoogle Scholar
  2. Atilla E, Ataca P, Ozyurek E, Erden I, Gurman G (2015) Successful bosutinib experience in an elderly acute lymphoblastic leukemia patient with suspected central nervous system involvement transformed from chronic myeloid leukemia. Case Rep Hematol 2015:689423PubMedPubMedCentralGoogle Scholar
  3. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buhring HJ et al (2004) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2):523–529CrossRefPubMedGoogle Scholar
  5. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44(23):3965–3977CrossRefPubMedGoogle Scholar
  6. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al (2014) Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124(4):511–518CrossRefPubMedGoogle Scholar
  7. Brummendorf TH, Gambacorti-Passerini C, Cortes J (2013) Efficacy and Safety of bosutinib for Philadelphia chromosome-positive leukaemia in older versus younger patients. J Clin Oncol (official journal of the American Society of Clinical Oncology), suppl. (Abstract 6511)Google Scholar
  8. Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D et al (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168(1):69–81CrossRefPubMedGoogle Scholar
  9. Brummendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P et al (2016) Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol 172(1):97–110CrossRefPubMedGoogle Scholar
  10. Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 23(3):610–617CrossRefPubMedGoogle Scholar
  11. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C (2006) SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66(4):2279–2286CrossRefPubMedGoogle Scholar
  12. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX et al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567–4576CrossRefPubMedPubMedCentralGoogle Scholar
  13. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30(28):3486–3492CrossRefPubMedPubMedCentralGoogle Scholar
  14. Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P et al (2016) Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol 91(12):1206–1214CrossRefPubMedPubMedCentralGoogle Scholar
  15. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW et al (2017) Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol, JCO2017747162Google Scholar
  16. Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A et al (2017) Effects of bosutinib treatment on renal function in patients with philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk 17(10):684–695 e6Google Scholar
  17. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175CrossRefPubMedGoogle Scholar
  18. Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29(5):999–1003CrossRefPubMedPubMedCentralGoogle Scholar
  19. Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G et al (2016) Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia 30(9):1844–1852CrossRefPubMedPubMedCentralGoogle Scholar
  20. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ et al (2012) Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 18(4):1092–1100CrossRefPubMedGoogle Scholar
  21. Gambacorti-Passerini C, Brummendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al (2014a) Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol 89(7):732–742CrossRefPubMedPubMedCentralGoogle Scholar
  22. Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V et al (2014b) Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 89(10):947–953CrossRefPubMedPubMedCentralGoogle Scholar
  23. Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brummendorf TH et al (2015) Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 90(9):755–768CrossRefPubMedPubMedCentralGoogle Scholar
  24. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63(2):375–381PubMedGoogle Scholar
  25. Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65(12):5358–5364CrossRefPubMedGoogle Scholar
  26. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13(8):559–571CrossRefPubMedPubMedCentralGoogle Scholar
  27. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096–2102CrossRefPubMedGoogle Scholar
  28. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28(10):1988–1992CrossRefPubMedGoogle Scholar
  29. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158(4):1153–1164CrossRefPubMedPubMedCentralGoogle Scholar
  30. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G (1985) Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 315(6022):758–761CrossRefPubMedGoogle Scholar
  31. Hsyu PH, Pignataro DS, Matschke K (2017) Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. Eur J Clin Pharmacol 73(1):49–56CrossRefPubMedGoogle Scholar
  32. Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T et al (2017) The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 9(391)Google Scholar
  33. Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K et al (2014) Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer 111(11):2058–2066CrossRefPubMedPubMedCentralGoogle Scholar
  34. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67(4):1580–1588CrossRefPubMedGoogle Scholar
  35. Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651–659CrossRefPubMedGoogle Scholar
  36. Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brummendorf TH, Su Y et al (2017) Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. CancerGoogle Scholar
  37. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW et al (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15):3403–3412CrossRefPubMedPubMedCentralGoogle Scholar
  38. Knight B, Garrett M, Cortes JE, Deininger MW (2017) Optimizing dose of bosutinib to minimize adverse events while maintaining efficacy in patients with newly diagnosed chronic myelogenous leukemia. In: ASH 59th annual meeting, Atlanta, GAGoogle Scholar
  39. Laneuville P (1995) Abl tyrosine protein kinase. Semin Immunol 7(4):255–266CrossRefPubMedGoogle Scholar
  40. Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS ONE 7(4):e29828CrossRefPubMedPubMedCentralGoogle Scholar
  41. Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1):19–26CrossRefPubMedPubMedCentralGoogle Scholar
  42. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243(2):503–508CrossRefPubMedGoogle Scholar
  43. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL (1992) Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28(2–3):372–377CrossRefPubMedGoogle Scholar
  44. Nowell PC, Hungerford DA (1961) Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 27:1013–1035PubMedGoogle Scholar
  45. Ocana A, Gil-Martin M, Martin M, Rojo F, Antolin S, Guerrero A, et al (2017) A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. Oncotarget 8(42):73144–73153Google Scholar
  46. Ono C, Hsyu PH, Abbas R, Loi CM, Yamazaki S (2017) Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: prediction of drug-drug and drug-disease interactions. Drug Metab Dispos 45(4):390–398CrossRefPubMedGoogle Scholar
  47. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52(17):4773–4778PubMedGoogle Scholar
  48. Patel AB, O’Hare T, Deininger MW (2017) Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am 31(4):589–612CrossRefPubMedPubMedCentralGoogle Scholar
  49. Pendergast AM (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8(2):174–181CrossRefPubMedGoogle Scholar
  50. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 66(23):11314–11322CrossRefPubMedGoogle Scholar
  51. Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M et al (2012) Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87(11):E125–E128CrossRefPubMedGoogle Scholar
  52. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5(3):172–183CrossRefPubMedGoogle Scholar
  53. Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G (2012) Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 53(12):2351–2361CrossRefPubMedGoogle Scholar
  54. Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648–1671CrossRefPubMedPubMedCentralGoogle Scholar
  55. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337–358CrossRefPubMedGoogle Scholar
  56. Sweeney WE Jr, von Vigier RO, Frost P, Avner ED (2008) Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19(7):1331–1341CrossRefPubMedPubMedCentralGoogle Scholar
  57. Sweeney WE, Frost P, Avner ED (2017) Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 6(4):188–200CrossRefPubMedPubMedCentralGoogle Scholar
  58. Tesar V, Ciechanowski K, Pei Y, Barash I, Shannon M, Li R et al (2017) Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 28(11):3404–3413CrossRefPubMedGoogle Scholar
  59. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609CrossRefPubMedGoogle Scholar
  60. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4):383–388CrossRefPubMedGoogle Scholar
  61. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185–1194CrossRefPubMedPubMedCentralGoogle Scholar
  62. Whiteley J, Reisman A, Shapiro M, Cortes J, Cella D (2016) Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin 32(8):1325–1334CrossRefPubMedGoogle Scholar
  63. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W et al (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366–376CrossRefPubMedPubMedCentralGoogle Scholar
  64. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW et al (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17(4):461–469CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Susanne Isfort
    • 1
  • Martina Crysandt
    • 1
  • Deniz Gezer
    • 1
  • Steffen Koschmieder
    • 1
  • Tim H. Brümmendorf
    • 1
  • Dominik Wolf
    • 2
  1. 1.Department of Hematology, Oncology, Hemostaseology and Stem Cell TransplantationUniversity Hospital RWTH AachenAachenGermany
  2. 2.Department of Oncology, Hematology, Immunoncology and RheumatologyUniversity Hospital BonnBonnGermany

Personalised recommendations